ArticleIndian journal of ophthalmology2026
Real-world management patterns and outcomes in normal-tension glaucoma.
Article in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThis study aimed to assess the clinical outcomes of normal-tension glaucoma (NTG) in real-world clinical practice, focusing on the clinical profile, pattern of treatment preferences, and visual field progression.
methodsA total of 875 eyes (476 patients) with NTG were included, with a mean age of 68 ± 10.6 years. Of these, 77 eyes had unilateral NTG and 399 had bilateral NTG. Ocular/systemic associations were recorded, and clinical variables, including the number of medications, intraocular pressure (IOP), and visual field parameters, were retrieved. Treatment options to achieve target IOP included topical medications (monotherapy or combination therapy) and surgical interventions. Visual field progression on guided progression analysis was available in 496 eyes with reliable data.
resultsAt baseline, 45% of eyes had severe glaucoma (mean deviation, MD = -13 ± 8.7 dB). While 92 eyes (including 5 unilateral NTG) were observed without medication, 783 eyes were on initiated on topical medications. At a mean follow-up of 32 ± 10.2 months, 22.2% of treated eyes showed visual field progression, compared to 10.8% in untreated eyes. The rate of progression in eyes that progressed was -2 ± 0.9 dB per year versus 0.2 ± 0.9 dB in stable eyes, P = 0.003. Multivariate analysis did not reveal any clinical or systemic association that predicted visual field progression.
conclusionThis study highlights the challenges of treating NTG in real-world clinical practice, where 45% patients presented with severe glaucoma. The absence of identifiable factors for progression suggests the need to search for newer risk factors for halting NTG progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.